Results 81 to 90 of about 52,117 (235)
American Journal of Medical Genetics Part A, EarlyView.ABSTRACT RASopathies are clinically overlapping neurodevelopmental syndromes resulting from germline mutations in genes involved in the rat sarcoma/mitogen‐activated protein kinases (RAS/MAPK) pathway. Historically, RASopathies have been described by clinical phenotypes, such as Noonan syndrome and Neurofibromatosis type I.
Anastasia‐Vasiliki Madenidou +6 more
wiley +1 more source
Height as a potential indicator of early life events predicting Parkinson's disease: a case-control study. [PDF]
, 2007 Aim of this study was to investigate the relationship between height in young adult age and Parkinson's disease (PD) risk. We included 266 persons affected by idiopathic PD.
AIELLO, Fabio +5 more
core +1 more source
Journal of Dr. NTR University of Health Sciences, 2015 Objective: The objective of this study is to determine the age at presentation, etiology and other characteristics of short children who are on growth hormone therapy (GHT) at a tertiary care hospital.
Babulreddy Hanmayyagari +5 more
doaj +1 more source
Small, EarlyView.Little is known about the effects of polystyrene nanoplastics (PS‐NPs) on gonadotropin releasing hormone (GnRH) neurons, which control puberty onset and fertility. By applying tailored in vitro GnRH neuron models, this article shows how PS‐NPs are internalized and impact hormone secretion and cell migration, through gene expression changes. Ultimately,
Federica Amoruso +14 more
wiley +1 more source
Aromatase Inhibitors in Male Adolescents with Idiopathic Short Stature [PDF]
, 2014 Introdução: O efeito dos fármacos inibidores da aromatase (IA) na estatura de jovens do sexo masculino com baixa estatura idiopática (BEI) tem vindo a ser estudado desde que foi evidenciado o papel dos estrogénios na paragem do crescimento linear.
Amaral, D, Fitas, AL, Lopes, L
core
A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation [PDF]
, 2001 We assessed the effectiveness and safety of 3 yr combined GH and GnRH agonist (GnRHa) treatment in a randomized controlled study in children with idiopathic short stature (ISS) or intrauterine growth retardation (IUGR ...
Delemarre-van de Waal, H.A. (Henriette) +8 more
core +3 more sources
Orthodontic treatment for a mandibular prognathic girl of short stature under growth hormone therapy
Journal of the Formosan Medical Association, 2013 This report presents a case of a 12-year-old girl with maxillary deficiency, mandibular prognathism, and facial asymmetry, undergoing growth hormone (GH) therapy due to idiopathic short stature.
Chin-Yun Pan +5 more
doaj +1 more source
Experimental and Therapeutic Medicine, 2021 The aim of the present study was to develop predictive models using clinical features and MRI texture features for distinguishing between growth hormone deficiency (GHD) and idiopathic short stature (ISS) in children with short stature.
Mengdi Cong +5 more
semanticscholar +1 more source
Acta Paediatrica, EarlyView.ABSTRACT Aim Medical gases, including nitric oxide, carbon monoxide, hydrogen sulphide and molecular hydrogen, have emerged as key regulators of redox balance and cellular signalling. This mini‐review examines their relevance to paediatric endocrine and neurodevelopmental pathways, domains particularly sensitive to oxidative and inflammatory ...
Roberto Paparella +3 more
wiley +1 more source
Identification of novel SHOX target genes in the developing limb using a transgenic mouse model [PDF]
, 2014 Deficiency of the human short stature homeobox-containing gene (SHOX) has been identified in several disorders characterized by reduced height and skeletal anomalies such as Turner syndrome, Léri-Weill dyschondrosteosis and Langer mesomelic dysplasia as ...
Beiser, Katja U. +11 more
core +5 more sources